Ademaj Adela, Puric Emsad, Timm Olaf, Kurti David, Marder Dietmar, Kern Thomas, Hälg Roger A, Rogers Susanne, Riesterer Oliver
Center for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, 5001 Aarau, Switzerland.
Doctoral Clinical Science Program, Medical Faculty, University of Zürich, 8032 Zürich, Switzerland.
Cancers (Basel). 2023 Feb 15;15(4):1241. doi: 10.3390/cancers15041241.
Hyperthermia (HT) in combination with radio(chemo)therapy (RCT) is a well-established cancer treatment strategy. This report analyses the quality of life (QoL), toxicity and survival outcomes in patients with different tumor entities who received HT in combination with RCT. The primary endpoint of this study was the assessment of QoL scale items 3 and 12 months after treatment in patients who were treated with palliative intent and curative intent, respectively. The secondary endpoints of this study were acute toxicities, 1-year overall survival (OS), and local progression-free survival (LPFS). Patients treated with curative intent experienced significant improvement in emotional functioning (EF), social functioning (SF), financial difficulties (FI) and insomnia (SL) 12 months after treatment. Patients had significantly improved FI and pain (PA) three months after palliative treatment. Acute toxicity of grade 3 or more was 26% during treatment and 4% after three months. The 1-year OS rates were 90% (95% CI: 79-96%) and 44% (95% CI: 31-59%) for patients treated with curative and palliative RCT combined with HT, respectively. Moreover, the 1-year LPFS rates were 94% (95% CI: 84-98%) for patients treated with curative intent and 64% (95% CI: 50-77%) for palliative patients. In summary, combined RCT and HT stabilized or improved QoL scale items for both curative and palliative indications.
热疗（HT）联合放射（化学）治疗（RCT）是一种成熟的癌症治疗策略。本报告分析了接受HT联合RCT治疗的不同肿瘤实体患者的生活质量（QoL）、毒性和生存结果。本研究的主要终点是分别评估接受姑息性治疗和根治性治疗的患者在治疗后3个月和12个月时的QoL量表项目。本研究的次要终点是急性毒性、1年总生存期（OS）和局部无进展生存期（LPFS）。接受根治性治疗的患者在治疗12个月后，情绪功能（EF）、社会功能（SF）、经济困难（FI）和失眠（SL）方面有显著改善。接受姑息性治疗的患者在治疗3个月后，FI和疼痛（PA）有显著改善。治疗期间3级或更高级别的急性毒性为26%，3个月后为4%。接受根治性RCT联合HT治疗的患者和接受姑息性RCT联合HT治疗的患者的1年OS率分别为90%（95%CI：79-96%）和44%（95%CI：31-59%）。此外，接受根治性治疗的患者的1年LPFS率为94%（95%CI：84-98%），姑息性治疗患者为64%（95%CI：50-77%）。总之，RCT与HT联合使用可使根治性和姑息性适应症的QoL量表项目稳定或改善。
